AR and Familial prostate cancer: When H4-pY88 epigenetic marks were reversed using an ACK1 inhibitor, this sensitized naïve and enzalutamide-resistant prostate cancer cells expressing reduced AR levels, leading to slowed CRPC tumor growth.